BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 2009;6:386-95. [PMID: 19718793 DOI: 10.1021/mp800115t] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 7.0] [Reference Citation Analysis]
2 Luis de Redín I, Boiero C, Martínez-Ohárriz MC, Agüeros M, Ramos R, Peñuelas I, Allemandi D, Llabot JM, Irache JM. Human serum albumin nanoparticles for ocular delivery of bevacizumab. Int J Pharm 2018;541:214-23. [PMID: 29481946 DOI: 10.1016/j.ijpharm.2018.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
3 Kameswaran M, Pandey U, Sarma HD, Samuel G. Preparation of (99m)Tc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model. Ann Nucl Med 2014;28:911-6. [PMID: 25038907 DOI: 10.1007/s12149-014-0887-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
4 Shepard KB, Vodak DT, Kuehl PJ, Revelli D, Zhou Y, Pluntze AM, Adam MS, Oddo JC, Switala L, Cape JL, Baumann JM, Banks M. Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation. AAPS PharmSciTech 2021;22:230. [PMID: 34467438 DOI: 10.1208/s12249-021-02095-7] [Reference Citation Analysis]
5 Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, Zhou M, Asiedu MK, Moser CD, Han S, Hu C, Banini BA, Oseini AM, Chen Y, Fang Y, Yang D, Shaleh HM, Wang S, Wu D, Song T, Lee JS, Thorgeirsson SS, Chevet E, Shah VH, Fernandez-Zapico ME, Roberts LR. Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Cancer Res 2017;77:632-45. [PMID: 27872089 DOI: 10.1158/0008-5472.CAN-15-2556] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
6 Montero AJ, Kwon D, Flores A, Kovacs K, Trent JC, Benedetto P, Rocha-Lima C, Merchan JR. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. Clin Cancer Res 2016;22:3209-17. [PMID: 26864210 DOI: 10.1158/1078-0432.CCR-15-2184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Unoki M, Kumamoto K, Harris CC. ING proteins as potential anticancer drug targets. Curr Drug Targets 2009;10:442-54. [PMID: 19442116 DOI: 10.2174/138945009788185059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
8 Qi L, Zhang Y, Zhang W, Wang Y, Han Y, Ding Y. The inhibition of colorectal cancer growth by the natural product macrocarpal I. Free Radic Biol Med 2021;162:383-91. [PMID: 33137468 DOI: 10.1016/j.freeradbiomed.2020.10.317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Burke L, Butler CT, Murphy A, Moran B, Gallagher WM, O'Sullivan J, Kennedy BN. Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Front Cell Dev Biol 2016;4:103. [PMID: 27709113 DOI: 10.3389/fcell.2016.00103] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
10 Garde Noguera J, Jantus-Lewintre E, Gil-Raga M, Evgenyeva E, Maciá Escalante S, Llombart-Cussac A, Camps Herrero C. Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Mol Clin Oncol 2017;6:403-8. [PMID: 28451421 DOI: 10.3892/mco.2017.1149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
11 Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: current challenges. Transl Gastroenterol Hepatol 2016;1:67. [PMID: 28138633 DOI: 10.21037/tgh.2016.08.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
12 Passot G, Dupré A, Rivoire M, Mohamed F, Bakrin N, Glehen O. Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. Clin Transl Oncol. 2012;14:931-936. [PMID: 22855172 DOI: 10.1007/s12094-012-0888-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Rio-Vilariño A, Del Puerto-Nevado L, García-Foncillas J, Cebrián A. Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance. Cancers (Basel) 2021;13:3757. [PMID: 34359657 DOI: 10.3390/cancers13153757] [Reference Citation Analysis]
14 Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol. 2009;10:72-79. [PMID: 19111247 DOI: 10.1016/s1470-2045(08)70335-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
15 Carter NJ. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging 2014;31:67-78. [PMID: 24276917 DOI: 10.1007/s40266-013-0140-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
16 Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010;103:1407-1414. [PMID: 20924372 DOI: 10.1038/sj.bjc.6605925] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 10.2] [Reference Citation Analysis]
17 Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med 2021;6:e10166. [PMID: 33532580 DOI: 10.1002/btm2.10166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kim ST, Park KH, Shin SW, Kim YH. Dose KRAS Mutation Status Affect on the Effect of VEGF Therapy in Metastatic Colon Cancer Patients? Cancer Res Treat 2014;46:48-54. [PMID: 24520223 DOI: 10.4143/crt.2014.46.1.48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
19 Quiros RM, Bui CL. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 2009;89:79-96, viii. [PMID: 19186232 DOI: 10.1016/j.suc.2008.09.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
20 Sousa F, Cruz A, Pinto IM, Sarmento B. Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity. Acta Biomater 2018;78:285-95. [PMID: 30036718 DOI: 10.1016/j.actbio.2018.07.040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
21 Islam R, Khan R, Ali A, Kollu V, Phan T, Chyou PH, Burmester JK, Kibriya MG. Clinical Factors Affecting Bevacizumab Efficacy With and Without Conventional Chemotherapy in Metastatic Colon Cancer. Am J Ther 2020;27:e500-6. [PMID: 32902937 DOI: 10.1097/MJT.0000000000000859] [Reference Citation Analysis]
22 Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, Mehrabi A, Kulu Y. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett 2021;21:448. [PMID: 33868486 DOI: 10.3892/ol.2021.12709] [Reference Citation Analysis]
23 Mody K, Baldeo C, Bekaii-Saab T. Antiangiogenic Therapy in Colorectal Cancer. Cancer J 2018;24:165-70. [PMID: 30119079 DOI: 10.1097/PPO.0000000000000328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 16.5] [Reference Citation Analysis]
24 Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, Kuo CH. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Anal Chim Acta 2018;1019:93-102. [PMID: 29625688 DOI: 10.1016/j.aca.2018.02.040] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
25 Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, Ibanez CE, Kasahara N, Gruber HE, Jolly DJ, Robbins JM. A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Mol Ther Oncolytics 2018;8:14-26. [PMID: 29322091 DOI: 10.1016/j.omto.2017.12.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
26 Kameswaran M, Pandey U, Gamre N, Vimalnath KV, Sarma HD, Dash A. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers. Appl Radiat Isot 2016;114:196-201. [PMID: 27258216 DOI: 10.1016/j.apradiso.2016.05.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Kameswaran M, Sarma HD, Dash A. Preclinical evaluation of 131I-Bevacizumab - A prospective agent for radioimmunotherapy in VEGF expressing cancers. Appl Radiat Isot 2017;123:109-13. [PMID: 28260607 DOI: 10.1016/j.apradiso.2017.02.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Baek YY, Lee DK, Kim J, Kim JH, Park W, Kim T, Han S, Jeoung D, You JC, Lee H, Won MH, Ha KS, Kwon YG, Kim YM. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism. Oncotarget 2017;8:11763-77. [PMID: 28052029 DOI: 10.18632/oncotarget.14343] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
29 Pavlidis ET, Pavlidis TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. World J Gastroenterol 2013; 19(31): 5051-5060 [PMID: 23964138 DOI: 10.3748/wjg.v19.i31.5051] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 7.5] [Reference Citation Analysis]
30 Reuveni D, Halperin D, Fabian I, Tsarfaty G, Askenasy N, Shalit I. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol 2010;79:1100-7. [PMID: 20025849 DOI: 10.1016/j.bcp.2009.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
31 Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Prasad N, Leth-Larsen R, Petersen M, Marušič M, Plavec J, Wengel J, Veedu RN. Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition. Chem Commun (Camb) 2015;51:9499-502. [PMID: 25968110 DOI: 10.1039/c5cc02756j] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
32 Raval SH, Singh RD, Joshi DV, Patel HB, Mody SK. Recent developments in receptor tyrosine kinases targeted anticancer therapy. Vet World 2016;9:80-90. [PMID: 27051190 DOI: 10.14202/vetworld.2016.80-90] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
33 Passot G, Bakrin N, Garnier L, Roux A, Vaudoyer D, Wallet F, Gilly F, Glehen O, Cotte E. Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment? European Journal of Cancer 2014;50:722-30. [DOI: 10.1016/j.ejca.2013.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ibarra-cabrera R, Mena-pérez SC, Bondani-guasti A, García-arrazola R. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America. Biotechnology Advances 2013;31:1333-43. [DOI: 10.1016/j.biotechadv.2013.05.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
35 Ozsoy Z, Ozsoy S, Gevrek F, Demir E, Benli I, Daldal E, Yenidogan E. Effect of bevacizumab on acetic acid–induced ulcerative colitis in rats. Journal of Surgical Research 2017;216:191-200. [DOI: 10.1016/j.jss.2017.05.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
36 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
37 Carrero I, Liu HC, Sikora AG, Milosavljevic A. Histoepigenetic analysis of HPV- and tobacco-associated head and neck cancer identifies both subtype-specific and common therapeutic targets despite divergent microenvironments. Oncogene 2019;38:3551-68. [PMID: 30655605 DOI: 10.1038/s41388-018-0659-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
38 Taniguchi S, Fujimori M, Sasaki T, Tsutsui H, Shimatani Y, Seki K, Amano J. Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci 2010;101:1925-32. [PMID: 20579076 DOI: 10.1111/j.1349-7006.2010.01628.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
39 Islam R, Chyou PH, Burmester JK. Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer 2013;4:330-5. [PMID: 23678369 DOI: 10.7150/jca.6083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
40 Singh SR, Chattannavar G, Ayachit A, Pimentel MC, Alfaro A, Tiwari S, Heranjal A, Subramanyam A, Braimah IZ, Dhami A, Sachdev P, Mansour A, Chhablani J. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections. Semin Ophthalmol 2020;35:2-6. [PMID: 31690175 DOI: 10.1080/08820538.2019.1686528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
41 Stalin J, Imhof BA, Coquoz O, Jeitziner R, Hammel P, McKee TA, Jemelin S, Poittevin M, Pocard M, Matthes T, Kaci R, Delorenzi M, Rüegg C, Miljkovic-Licina M. Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy. Cancers (Basel) 2021;13:4625. [PMID: 34572851 DOI: 10.3390/cancers13184625] [Reference Citation Analysis]
42 Syed YY, McKeage K. Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs 2015;75:1435-45. [PMID: 26220913 DOI: 10.1007/s40265-015-0444-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
43 Watters A, Epstein J, Agulnik M. Oral complications of targeted cancer therapies: A narrative literature review. Oral Oncology 2011;47:441-8. [DOI: 10.1016/j.oraloncology.2011.03.028] [Cited by in Crossref: 82] [Cited by in F6Publishing: 54] [Article Influence: 8.2] [Reference Citation Analysis]
44 Mccormack PL, Keam SJ. Spotlight on Bevacizumab in Metastatic Colorectal Cancer†: . BioDrugs 2008;22:339-41. [DOI: 10.2165/00063030-200822050-00006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
45 Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008;44:2350-6. [PMID: 18789679 DOI: 10.1016/j.ejca.2008.07.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
46 Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:1-13. [PMID: 21752724 DOI: 10.1016/j.clcc.2011.05.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 8.2] [Reference Citation Analysis]
47 Grau S, Thorsteinsdottir J, von Baumgarten L, Winkler F, Tonn J, Schichor C. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol 2011;104:103-12. [DOI: 10.1007/s11060-010-0480-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
48 Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 2013;9:2253-62. [PMID: 24045230 DOI: 10.4161/hv.26498] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
49 Dahiya R, Dahiya S. Ocular Delivery of Peptides and Proteins. In: Patel JK, Sutariya V, Kanwar JR, Pathak YV, editors. Drug Delivery for the Retina and Posterior Segment Disease. Cham: Springer International Publishing; 2018. pp. 411-37. [DOI: 10.1007/978-3-319-95807-1_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G. Cost-Minimization Analysis of the Treatment of Patients With Metastatic Colorectal Cancer in Greece. Clinical Therapeutics 2012;34:2132-42. [DOI: 10.1016/j.clinthera.2012.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
51 Garattini L, van de Vooren K, Zaniboni A. Ethics for end-of-life treatments: Metastatic colorectal cancer is one example. Health Policy 2013;109:97-103. [DOI: 10.1016/j.healthpol.2012.08.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
52 Pavlidis ET, Ballas KD, Symeonidis NG, Psarras K, Koliakos G, Kouzi-Koliakos K, Topouridou K, Rafailidis SF, Pavlidis TE, Marakis GN. The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis. 2010;25:1465-1473. [PMID: 20689957 DOI: 10.1007/s00384-010-1039-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
53 Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 2009;14:1095-105. [DOI: 10.1634/theoncologist.2009-0152] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]